Ivan PETYAEV

Appl. No. 10/574,852

Attv. Ref.: 620-433

Amendment

January 23, 2009

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claim 1-11. (Canceled)

12. (Currently Amended) A method for reducing apolipoprotein-B levels in the vascular system without reducing LDL-cholesterol levels in an individual in need thereof comprising simultaneously administering azithromycin and acetylsalicylic acid to the

individual, wherein the individual has hyperlipidemia, and said apolipoprotein-B levels in

the vascular system of the individual are reduced without reducing said LDL-cholesterol

levels in the individual.

13. (Previously Presented) A method according to claim 12 wherein the total

level of cholesterol is reduced in the vascular system of the individual.

Claim 14. (Canceled)

Claim 15. (Canceled)

Claim 16. (Canceled)

Claim 17. (Canceled)

Claim 18. (Canceled)

Claim 19. (Canceled)

Claim 20. (Canceled)

21. (Currently Amended) A method for reducing apolipoprotein-B levels in the

vascular system without reducing LDL-cholesterol levels in an individual in need thereof

comprising simultaneously administering azithromycin and acetylsalicylic acid to the

individual, wherein the individual has hyperlipidemia; wherein said azithromycin and

- 2 -

1429373

Ivan PETYAEV

Appl. No. 10/574,852

Atty. Ref.: 620-433

Amendment

January 23, 2009

said acetylsalicylic acid are administered to the individual in an amount sufficient to

reduce apolipoprotein-B levels in the vascular system without reducing LDL-cholesterol

levels in said individual

A method according to claim according to claim 12 wherein azithromycin and the

acetylsalicylic acid are administered simultaneously.

Claim 22. (Canceled)

Claims 23-26. (Canceled)

Claim 27. (Canceled)

Claim 28. (Canceled)

29. (Previously Presented) A method according to clam 12 wherein the

individual does not have an atherosclerotic condition.

Claim 30. (Canceled)

Claim 31. (Canceled)

32. (Currently Amended) A method for reducing apolipoprotein-B levels in the

vascular system without reducing LDL-cholesterol levels in an individual in need thereof

comprising;

simultaneously administering azithromycin and [[asprin]]aspirin to the individual,

wherein said azithromycin and said acetylsalicylic acid are administered to the individual

in an amount sufficient to reduce apolipoprotein-B levels in the vascular system without

reducing LDL-cholesterol levels in said individual; and,

determining levels of apolipoprotein-B and LDL-cholesterol in the vascular

system of said individual following said administration,

- 3 -

1429373

Ivan PETYAEV

Appl. No. 10/574,852

Atty. Ref.: 620-433 Amendment

January 23, 2009

wherein the individual has hyperlipidemia.

33. (Previously Presented) A method according to claim 12 comprising determining the level of apolipoprotein-B and LDL-cholesterol in the vascular system of said individual following said administration.

34. (Previously Presented) A method according to claim 12 comprising determining the reduction in apolipoprotein-B levels and the lack of reduction in LDL-cholesterol levels in the vascular system of said individual, following said administration.

35. (new) A method according to claim 21 wherein the total level of cholesterol is reduced in the vascular system of the individual.

36. (new) A method according to clam 21 wherein the individual does not have an atherosclerotic condition.

37. (new) A method according to claim 21 comprising determining the level of apolipoprotein-B and LDL-cholesterol in the vascular system of said individual following said administration.

38. (new) A method according to claim 21 comprising determining the reduction in apolipoprotein-B levels and the lack of reduction in LDL-cholesterol levels in the vascular system of said individual, following said administration.